107 related articles for article (PubMed ID: 8977970)
1. [Prognosis of multiple myeloma treated with conventional chemotherapy has not improved in 20 years].
Dubost JJ; Ristori JM; Soubrier M; Zbadi K; Bussière JL; Sauvezie B
Rev Med Interne; 1996; 17(11):895-900. PubMed ID: 8977970
[TBL] [Abstract][Full Text] [Related]
2. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
[TBL] [Abstract][Full Text] [Related]
3. [Clinical features and survival of Chilean patients with multiple myeloma].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2007 Sep; 135(9):1111-7. PubMed ID: 18064364
[TBL] [Abstract][Full Text] [Related]
4. Prognostic assessment of the Durie and Salmon staging system in patients with multiple myeloma.
Spasov E; Goranova V
Folia Med (Plovdiv); 1998; 40(3B Suppl 3):121-3. PubMed ID: 10206011
[TBL] [Abstract][Full Text] [Related]
5. International prognostic index (IPI)--a critical comparison with five multiple myeloma staging systems in the group of 270 patients treated by conventional chemotherapy.
Scudla V; Zemanova M; Minarik J; Bacovsky J; Ordeltova M; Indrak K; Budikova M; Dusek L; Farbiakova V
Neoplasma; 2006; 53(4):277-84. PubMed ID: 16830053
[TBL] [Abstract][Full Text] [Related]
6. Critical study of staging in multiple myeloma.
Pennec Y; Mottier D; Youinou P; Asselain B; Chavance M; Le Goff P; Le Prise PY; Miossec P; Le Menn G
Scand J Haematol; 1983 Feb; 30(2):183-90. PubMed ID: 6860419
[TBL] [Abstract][Full Text] [Related]
7. VAD-PECC regimen in the treatment of advanced-stage multiple myeloma.
Delain M; Linassier C; Petitdidier C; Goupille P; Luthier F; Combe M; Reisenleiter M; Benboubker L; Lamagnère JP; Colombat P
J Clin Oncol; 1994 Dec; 12(12):2706-13. PubMed ID: 7989948
[TBL] [Abstract][Full Text] [Related]
8. A comparison of two staging systems for myeloma.
Vercelli D; Cozzolino F; Di Guglielmo R
Nouv Rev Fr Hematol (1978); 1981; 23(2):107-10. PubMed ID: 7290984
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and therapeutic results in multiple myeloma.
Nagai M; Kitahara T; Minato K; Takenaka T; Konda C; Seki S; Shimoyama M
Jpn J Clin Oncol; 1985 Sep; 15(3):505-15. PubMed ID: 4057632
[TBL] [Abstract][Full Text] [Related]
10. [Clinical study of multiple myeloma: a report of 182 cases].
Xu L; Wang Y; Wu W; Yan H; Gao XD; Yu Q; Shen ZX; Mi JQ
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(14):972-7. PubMed ID: 20646647
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and staging systems of multiple myeloma:
Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
[TBL] [Abstract][Full Text] [Related]
12. The Role of
Deng S; Zhang B; Zhou Y; Xu X; Li J; Sang S; Zhang W
Contrast Media Mol Imaging; 2018; 2018():4198673. PubMed ID: 30154686
[TBL] [Abstract][Full Text] [Related]
13. International staging system for multiple myeloma.
Greipp PR; San Miguel J; Durie BG; Crowley JJ; Barlogie B; Bladé J; Boccadoro M; Child JA; Avet-Loiseau H; Kyle RA; Lahuerta JJ; Ludwig H; Morgan G; Powles R; Shimizu K; Shustik C; Sonneveld P; Tosi P; Turesson I; Westin J
J Clin Oncol; 2005 May; 23(15):3412-20. PubMed ID: 15809451
[TBL] [Abstract][Full Text] [Related]
14. Improvement of Durie & Salmon staging for multiple myeloma by adding platelet count as a stratifying variable: a multivariate regression analysis of 163 untreated patients.
Cavo M; Galieni P; Grimaldi M; Zuffa E; Bonelli MA; Gobbi M; Tura S
Eur J Haematol Suppl; 1989; 51():99-104. PubMed ID: 2697598
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of clinical, laboratory, and histological characteristics in multiple myeloma: improved definition of risk groups.
Peest D; Coldewey R; Deicher H; Sailer M; Vykoupil C; Leo R; Georgii A; Karow J; Hoeppner E; Diehl V
Eur J Cancer; 1993; 29A(7):978-83. PubMed ID: 8499152
[TBL] [Abstract][Full Text] [Related]
16. [Long-term survival and prognostic factors in multiple myeloma treated with conventional chemotherapy. Report of 109 cases].
Ben Abid H; Meddeb B; Ben Abdallah M; Bel Hadj Ali Z; Hafsia R; Ben Lakhal R; Gouider E; Aissaoui L; Landoulsi I; ben Abdeladhim A; Hafsia A
Tunis Med; 2000 Dec; 78(12):705-12. PubMed ID: 11155374
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic and therapeutic significance of bone marrow biopsy in multiple myeloma. Analysis of 31 stage II A and III A patients].
Paule B; Quillard J; Medicis P; Bourgeois P; Grossin M; Bisson M; Kahn MF
Rev Rhum Mal Osteoartic; 1988 Jan; 55(1):27-32. PubMed ID: 3353673
[TBL] [Abstract][Full Text] [Related]
18. [Screening of prognostic factors and comparing of staging systems of multiple myeloma].
Li J; Wu XB; Zhou Y; Wang X; Chen JX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):926-9. PubMed ID: 22931656
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of the new international staging system in multiple myeloma. Comparison with Durie-Salmon staging system].
Conté L G; Figueroa M G; Lois V V; Cabrera C ME; León R A; García L H; Rojas R H
Rev Med Chil; 2008 Jan; 136(1):7-12. PubMed ID: 18483648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
